LMBRD2

Across TCGA pan-cancer cohorts, LMBRD2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated LMBRD2 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher LMBRD2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LMBRD2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

STAD, UCEC, and COAD are the cancer types where LMBRD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.109	0.691	<.001	36	view →
UCEC	DFS	Median	All	1.000	0.612	.001	36	view →
COAD	OS	Median	III,IV	0.168	0.786	<.001	15	view →
LUSC	OS	Median	III,IV	0.011	0.684	<.001	12	view →
LIHC	OS	Median	All	0.149	0.704	.019	9	view →
SARC	DFS	Median	All	0.179	0.612	.024	6	view →
BLCA	OS	Median	IV	0.085	0.599	<.001	6	view →
SKCM	DFS	Median	III,IV	0.840	0.237	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

LMBRD2–STAD (OS)

Open the STAD breakdown →